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Summary 
The protective effect of ischaemic postconditioning (short cycles of reperfusion and 
reocclusion of a previously occluded vessel) was identified over a decade ago 
commanding intense interest as an approach for modifying reperfusion injury which 
contributes to infarct size in acute myocardial infarction. Elucidation of the major 
mechanisms of postconditioning has identified potential pharmacological targets for 
limitation of reperfusion injury. These include ligands for membrane-associated 
receptors, activators of phosphokinase survival signalling pathways and inhibitors of 
the mitochondrial permeability transition pore. In experimental models, numerous 
agents that target these mechanisms have shown promise as postconditioning 
mimetics. Nevertheless, clinical studies of ischaemic postconditioning and 
pharmacological postconditioning mimetics have been equivocal. The majority of 
experimental research is conducted in animal models which do not fully portray the 
complexity of risk factors and comorbidities with which patients present and which we 
now know modify the signalling pathways recruited in postconditioning. Cohort size 
and power, patient selection and deficiencies in clinical infarct size estimation may all 
represent major obstacles to assessing the therapeutic efficacy of postconditioning. 
Furthermore, chronic treatment of these patients with drugs like ACE inhibitors, statins, 
nitrates etc. may modify signalling, inhibiting the protective effect of postconditioning 
mimetics, or conversely, induce a maximally protected state wherein no further benefit 
can be demonstrated. Arguably, successful translation of postconditioning can not 
occur until all of these issues are addressed i.e. experimental investigation requires 
more complex models that better reflect the clinical setting, while clinical investigation 
requires bigger trials with appropriate patient selection and standardisation of clinical 
infarct size measurements. 
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Abbreviations 
5-HD: 5-hydroxydecanoate 
ACE: angiotensin converting enzyme 
ACS: acute coronary syndrome 
Akt: protein kinase B 
AMI: acute myocardial infarction 
ANP: atrial natriuretic peptide 
BNP: B-type natriuretic peptide
cGMP: 3’,5’-cyclic guanosine monophosphate 
CK: creatine kinase 
CK-MB: creatine kinase assay 
CMR: cardio magnetic resonance  
CYP-D: cyclophilin-D 
Cys-A: cyclosporine-A 
eNOS: endothelial nitric oxide synthase 
EPO: erythropoietin 
ERK: extracellular regulated kinase 
GSK-3β: glycogen synthase-3β
MKATP: ATP sensitive mitochondrial potassium channel 
MPTP: mitochondrial permeability transition pore 
NO: nitric oxide 
NPR: natriuretic peptide receptor 
PCI: percutaneous coronary intervention 
pGC: particulate guanylyl cyclase 
PI3K: phosphatidyl inositol 3 kinase 
PKC: protein kinase C 
PKG: protein kinase G 
PLB: phospholamban 
RISK: reperfusion injury salvage kinase 
ROCK: Rho-associated protein kinase 
ROS: reactive oxygen species 
SAFE: survivor activating factor enhancement 
SERCA: sarcoplasmic/endoplasmic reticulum calcium ATPase 
sGC: soluble guanylyl cyclase 
STAT3: signal transducer and activator of transcription 3
STEMI: ST-elevated myocardial infarction
TNF: tumour necrosis factor 
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Development of the postconditioning paradigm for cardioprotection 
Death due to acute myocardial infarction (AMI) has declined steadily in the 
economically developed countries during the last 50 years. Since the 1980s, the 
development of reperfusion therapies as the “standard of care” for AMI has contributed 
markedly to the decline in early mortality. However, while case fatality rate has 
declined, there is evidence of an increasing incidence of chronic heart failure in AMI 
survivors. It is likely that infarct size is a major determinant of myocardial remodelling 
processes that predispose to subsequent heart failure development. Thus, prompt 
reperfusion is necessary and effective to limit the development of ischaemic necrosis 
during AMI but it seems plausible that further limitation of infarction is desirable to 
reduce long term morbidity and mortality due to heart failure. The identification of 
potential adjunctive infarct-limiting treatments has been a goal of experimental 
cardioprotection research for several decades. A vast array of pharmacological and 
other interventions have been described. A review of all of these is beyond the scope 
of this paper but we wish to highlight here three pivotal conceptual developments that 
emerged over several decades and converged to provide a new cardioprotection 
paradigm around 2005.  
1. A mechanism of tissue injury specifically associated with reperfusion, termed “lethal 
reperfusion injury”, had been proposed as long ago as the late 1970s (Ashraf et al., 
1978; Hearse et al., 1978). This concept implied the rapid irreversible injury, or 
accelerated death, of cells still viable at the end of an ischaemic period as a result of 
the sudden reintroduction of oxygen to ischaemic tissue. This reperfusion-associated 
cell death would be expected to contribute to final infarct size in reperfused AMI. For 
two decades, the concept of lethal reperfusion injury proved to be controversial. The 
proposed molecular and cellular mechanisms of lethality were diverse and poorly 
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defined. Most importantly, experimental pharmacological interventions specifically 
targeted at reperfusion were not consistent in their infarct-limiting ability. However, 
from the mid-1990s, evidence was accruing that apoptotic signals are activated during 
early reperfusion and that reperfused myocardium displays hallmarks of apoptosis. 
Although the quantitative contribution of apoptosis to infarct size is likely to be small, 
experimental activation of anti-apoptotic survival signals and inhibition of caspases, 
were found to limit infarct size in experimental models. This work led to the 
development by Yellon and colleagues of a general hypothesis that attenuation of 
lethal reperfusion injury and limitation of infarct size could be induced by activating 
anti-apoptotic survival signals termed “reperfusion injury salvage kinases” (RISK 
pathway) (Hausenloy et al., 2004).  
2. In 1986, Murry et al. made the experimental observation that brief periods of 
ischaemia preceding AMI led to an acute adaptation of myocardium that limited infarct 
size (Murry et al., 1986). This phenomenon was termed ischaemic preconditioning. 
Intensive research throughout the 1990s revealed that ischaemic preconditioning is 
associated with the recruitment of a number of autacoid-stimulated signal transduction 
mechanisms which enhance the tolerance of myocardium to ischaemia-reperfusion 
insult, and thereby limit infarct size. The first autacoid to be identified in relation to the 
preconditioning mechanism was adenosine. This factor had been investigated 
extensively prior to the discovery of preconditioning in relation to nucleotide 
metabolism in ischaemia (Berne et al., 1974; Berne, 1980). Indeed, ATP catabolism 
had been an area of active investigation in the laboratory of Reimer and Jennings for 
many years (Reimer et al., 1986) and led directly to the experimental protocol that 
identified preconditioning (Murry et al., 1986). Subsequently through the 1990s several 
other autacoid factors and numerous intracellular signal transduction mechanisms 
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were identified, all presumed only to be effective if activated prior to the onset of AMI. 
While preconditioning mechanisms induce a marked and very reproducible infarct-
limiting effect, the clinical utility of therapies based on these mechanisms is extremely 
limited since pre-ischaemic treatment is implausible for the majority of AMI patients in 
whom coronary thrombosis is sudden and unheralded. 
3. In 2003, Vinten-Johansen and colleagues reported the observation that intermittent 
repetitive re-occlusion of the infarct-related coronary artery during the early moments 
of reperfusion in an experimental model of AMI was able to limit infarct size as 
effectively as ischaemic preconditioning (Zhao et al., 2003). This reperfusion-specific 
intervention is termed ischaemic postconditioning. Subsequent early research on 
postconditioning was remarkable for several reasons. First, postconditioning 
confirmed that lethal reperfusion injury contributes significantly to final infarct size. 
Second, both ischaemic preconditioning and ischaemic postconditioning were shown 
to involve activation at reperfusion of the RISK pathway identified a few years 
previously (Kin et al., 2004). Clearly, the temporal characteristics of postconditioning 
highlight the relative importance of reperfusion injury in AMI, but has no effect on 
ischaemic injury even though ischaemia is the sine qua non of AMI.  
Introduction of the postconditioning paradigm for cardioprotection has attracted huge 
interest in the possibility of therapeutic intervention at reperfusion to limit the injurious 
combined effect of ischaemia and reperfusion. In this respect, intervention at 
reperfusion with conditioning protocols or with pharmacological agents that 
recapitulate conditioning mechanisms can truly be said to represent a paradigm shift 
in the field.  
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Characteristics of postconditioning 
Interventions applied in the early reperfusion period to augment tissue salvage, 
beyond that achieved by reperfusion alone, are now often described as 
postconditioning treatments. Such interventions may take several forms and it is 
important to distinguish between them. Here we provide a brief overview of these 
interventions and their major characteristics: for further discussion the reader is 
referred to more detailed reviews elsewhere (Burley et al., 2009; Ovize et al., 2010; 
Shi et al., 2012; Hausenloy, 2013). 
Myocardial ischaemic postconditioning 
Postconditioning to limit infarct size was first formally described and characterised in 
the open-chest dog by Zhao et al. (2003). This form of postconditioning is referred to 
as myocardial ischaemic postconditioning, classical postconditioning, or mechanical 
postconditioning. It has been described in several other experimental species (mouse, 
rat, rabbit and pig) in vivo (Yang et al., 2004; Schwartz et al., 2006; Tang et al., 2006; 
Gomez et al., 2008); in isolated rodent heart preparations (Tsang et al., 2004; Heusch
et al., 2006); in humans and in isolated human myocardium (Sivaraman et al., 2007). 
The major characteristic of the intervention is that brief (typically 10-30 second), 
repetitive periods (3-10 cycles) of ischaemia, interspersed with brief (10-30 second) 
periods of reperfusion, are achieved by physical occlusion and reperfusion of the 
infarct-related coronary artery immediately following the index ischaemic event (see 
Figure 1). Most studies suggest that the timing of the intervention is critical to the 
outcome in reducing infarct size. A delay of more than one minute in instituting the first 
re-occlusion of the coronary artery was associated with a loss of protection (Skyschally
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et al., 2009). This concurs with the prevailing view that lethal reperfusion injury, 
associated with opening of the mitochondrial permeability transition pore (MPTP), 
occurs within the first few minutes of reperfusion (Griffiths et al., 1995; Di Lisa et al., 
2001). However, limited evidence in mouse heart suggests that myocardial ischaemic 
postconditioning can limit infarct size if instituted even 30 minutes after reperfusion 
(Roubille et al., 2011). This effect has been termed “delayed” ischaemic 
postconditioning. Whether it is a phenomenon generalizable to other species, 
including humans, is not clear. However, it has been suggested that the observation 
supports the concept of a gradually evolving “wavefront of reperfusion injury”, 
susceptible to later intervention.  
Although ischaemic postconditioning has been reported in every animal species 
examined, considerable variation in the extent of infarct limitation is seen between 
species and laboratories. Murine models of postconditioning typically display 30% 
relative reduction in infarct size whereas in larger models such as the rabbit and canine 
infarct size limitation is around 50% (Vinten-Johansen et al., 2011). Considerable 
variation is found in the multitude of postconditioning protocols used and in the 
duration of index ischaemia employed in these experimental models. Some data 
suggest that the threshold for ischaemic postconditioning rises as index ischaemic 
duration increases. There have been some reports of the failure of ischaemic 
postconditioning to limit infarct size (Schwartz et al., 2006; Dow et al., 2007; Hale et 
al., 2008). Typically those studies which failed to show infarct limitation following 
postconditioning used briefer index ischaemia, and for larger animals, shorter 
postconditioning cycles. It is clear that there is not one protocol that suits all models 
and differences in protocols may account for the varying degrees of protection. 
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In addition to limiting infarct size, ischaemic postconditioning has been reported to limit 
the severity of other deleterious consequences of reperfusion. These include the 
development of arrhythmias in the rat heart (Dow et al., 2008), cardiomyocyte 
apoptosis and the extent of vascular injury (Schwartz et al., 2012). 
Remote ischaemic postconditioning 
Numerous experimental and clinical observations suggest that intermittent ischaemia 
at the onset of myocardial reperfusion of tissues and organs remote from the heart 
can limit myocardial infarct size (see Figure 1). This phenomenon, called remote 
ischaemic postconditioning (or inter-organ postconditioning), is the subject of a 
comprehensive review elsewhere in this issue (Schmidt et al. this issue). The most 
frequently applied remote ischaemic postconditioning intervention, in both 
experimental and clinical models, is intermittent limb ischaemia performed at the onset 
of myocardial reperfusion (Kharbanda et al., 2001; Loukogeorgakis et al., 2006). The 
potential utility of such a simple intervention (e.g. repeated inflation of a blood pressure 
cuff) has attracted considerable interest, further augmented by the recognition that 
some benefit also accrues if the remote postconditioning intervention is delayed by 30 
minutes after myocardial reperfusion (“delayed remote ischaemic postconditioning”). 
The biological mechanisms of remote ischaemic postconditioning are unclear, but 
there appears to be a dependency on several interacting factors, including neuronal 
and humoral factors as well as transmission of unknown factors via microvesicles 
(Giricz et al., 2014). 
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Pharmacological postconditioning 
The administration of pharmacological or other biologically active agents during early 
reperfusion to effect cardioprotection is frequently termed pharmacological 
postconditioning. For clarity and precision, we believe that the term should be reserved 
strictly for approaches that recruit or mimic the established pathways associated with 
ischaemic postconditioning. These approaches would include pharmacological 
agonists for receptors that are known to participate in ischaemic postconditioning (e.g. 
adenosine A2 receptor ligands, or kinin B2 receptor ligands); or activators of 
established signal transduction mechanisms participating in ischemic postconditioning 
(e.g. statins and volatile anaesthetics activating the PI3K/Akt pathway, or NO donors 
activating the cGMP/PKG pathway). It is usual for administration of such agents to be 
commenced shortly before reperfusion or immediately at reperfusion onset. A wide 
variety of agents, unrelated directly to the mechanisms of ischaemic postconditioning, 
have been reported over many decades as adjuncts to reperfusion. These include 
calcium channel blockers (Kloner et al., 1991), magnesium salts (Antman, 1995), 
caspase inhibitors (Mocanu et al., 2000) and adrenoreceptor antagonists (Broadley et 
al., 2004). Whether or not they are effective at limiting infarct size during reperfusion, 
such pharmacological treatments should not be described as postconditioning 
mimetics. 
Other modified reperfusion approaches 
Several years before the formal description of ischaemic postconditioning it was 
recognised that modified forms of reperfusion could limit reperfusion injury. Most 
notable are staged (gradual) reperfusion and acidic reperfusion (see Figure 1). Several 
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surgical studies in the 1980s showed that gradual, rather than rapid, restoration of 
coronary blood flow mitigated against the development of reperfusion injuries 
(arrhythmias and stunning) (Casale et al., 1984; Preuss et al., 1987). This manoeuvre 
was later shown to limit infarct size (Sato et al., 1997). Similarly, mild acidification of 
the blood or crystalloid perfusate during early reperfusion showed a similarly protective 
effect (Inserte et al., 2008). Our understanding of the molecular mechanisms of 
reperfusion injury has led to speculation that both manoeuvres limit the opening of 
MPTP during early reperfusion, a mechanism shared in common with the various 
forms of postconditioning and discussed in more detail below. 
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Overview of mechanisms of ischaemic postconditioning
The prevailing conceptual model (see Figure 2) within which the majority of work on 
ischaemic postconditioning is currently undertaken postulates opening of MPTP 
during the early minutes of reperfusion as being a critical event leading to cell death. 
In postconditioned myocardium, a number of complex interlinked signalling pathways 
are activated by intracellular factors and extracellular autacoids. These signalling 
pathways ultimately impinge on MPTP, reducing the probability of its opening. This 
mechanistic framework has been built up through a considerable body of experimental 
work, including pharmacological and genetic targeting of these pathways, autacoids 
and components of the MPTP. We will now describe the key evidence supporting the 
current model, beginning with a discussion of the pivotal role of MPTP. 
Mitochondrial permeability transition 
Hunter and Haworth (1979) and Crompton (1987) identified the MPTP as a non-
specific channel of defined diameter spanning the mitochondrial inner and outer 
membranes. More recent work by Halestrap and colleagues made the association 
between reperfusion and the formation of this pore in an active state. They observed 
that opening of the MPTP is enhanced by adenine nucleotide depletion, as well as 
elevated phosphate and oxidative stress, which are biochemical anomalies associated 
with ischaemia-reperfusion injury (Halestrap et al., 1998). Opening of MPTP permits 
the passage of molecules up to 1.5 kDa and, with the entry into the mitochondrial 
matrix of H+, results in uncoupling of oxidative phosphorylation, ATP depletion and 
the onset of cell death by necrosis. Work by Crompton et al. (1988) and Griffiths et al. 
(1993; 1995) provided direct evidence of MPTP opening at reperfusion, but not during 
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ischaemia. Particular features of the intracellular environment in reperfusion appear to 
contribute to this activation of MPTP. They include oxidising conditions associated with 
reactive oxygen species (ROS) generation, intracellular Ca2+ overload and the 
reversal of intracellular acidosis as a result of H+ washout (Buja, 2013). It has been 
suggested that ischaemic postconditioning and postconditioning mimetic stimuli 
attenuate opening of the MPTP by reducing intracellular Ca2+  overload and limiting 
ROS generation (Leung et al., 2008). 
It remains unclear how Ca2+, ROS and H+ interact with the MPTP, but it has been 
reported that binding of adenine nucleotide translocase ligands to cyclophilin-D 
(CYP-D), a subunit of the MPTP, increases sensitivity to Ca2+. Mice deficient in CYP-
D could not be protected by an ischaemic postconditioning stimulus (Elrod et al., 
2010). On the other hand, cyclosporine-A (Cys-A) which inhibits MPTP opening by 
binding to cyclophilin-D limits infarct size when administered at reperfusion in most 
animal models tested and in humans (Gedik et al., 2013). 
Mitochondrial KATP (MKATP) channels offer another cytoprotective target, through 
regulating ROS production and Ca2+ overload. Perfusion with the KATP channel blocker 
5-HD (5-hydroxydecanoate) abolished postconditioning protection in the rat, whereas 
the KATP channel opener diazoxide significantly improved cardiac contractile activity 
(Jin et al., 2012). It is further suggested that intermittent targeting of the MKATP channel 
during reperfusion, mimicking postconditioning, affords cardioprotection by ROS 
compartmentalisation (Penna et al., 2007). Interestingly postconditioning was blocked 
by administration of an antioxidant during early reperfusion. It is proposed that the 
early generation of ROS may trigger MKATP channel opening  and protein kinase C 
(PKC) activation which are required for protection, supported by the notion that a 
channel blocker and PKC inhibitor abrogated protection (Yang et al., 2004). 
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Subsequent reduction in ROS however may prevent MPTP opening (Clarke et al., 
2008). 
Receptor-mediated mechanisms 
The involvement of a number of extracellular autacoid factors, elaborated or enhanced 
as a result of ischaemic postconditioning, has been explored extensively. These 
factors are the subject of a comprehensive discussion elsewhere in this issue 
(Kleinbongard and Heusch, 2014 this issue) and the interested reader is referred 
there. In brief outline, the autacoids that have received most attention include 
adenosine, bradykinin, and opioid peptides. Several studies have demonstrated that 
ischaemic postconditioning delays the washout of endogenous adenosine and 
subsequent receptor activation affords protection (Kin et al., 2005). Different receptor 
subtypes are implicated in different species with A2A and A3 important in rat (Kin et al., 
2005), whilst A2B signalling is required in the post conditioned rabbit heart (Philipp et 
al., 2006). Bradykinin B2 receptors have also been implicated in postconditioning in 
the rat perfused with the B2 receptor antagonist HOE140, which abrogated protection 
(Penna et al., 2007). Interestingly perfusion of bradykinin for 3 min during early 
reperfusion was unable to afford protection, yet intermittent perfusion in a protocol to 
match mechanical postconditioning demonstrated comparable infarct limitation. This 
protocol was unsuccessful when using adenosine. The significance of the protection 
afforded by bradykinin perfusion in this model remains to be elucidated. 
Most recently the opioid receptor has been reported to play a part in 
postconditioning. The opioid receptor antagonist naloxone abolished the protection 
afforded by postconditioning alone (Zatta et al., 2008). Similarly to the observations 
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made with adenosine, postconditioning appears to prevent the washout of 
pro-enkephalin, suggesting a build-up of endogenous opioid during postconditioning. 
These observations are supported by recent findings that report that  opioid 
receptor activation limits infarct size during early reperfusion, an effect that was 
blocked by extracellular regulated kinase (ERK)1/2 inhibition (Kim et al., 2011). 
Protein kinase mechanisms 
The third and most complex element of the postconditioning mechanism is 
transduction of the extracellular signals described above to the mitochondria, leading 
to inhibition of MPTP (see above). Signal transduction is via a number of pathways 
involving protein kinase activation, often sequentially. The discussion below focusses 
on the major kinases explored to date. While these are grouped discretely for the 
purposes of this discussion, it needs to be recognised that considerable overlap and 
cross-talk likely exists between these cascades. 
RISK pathway (PI3K/Akt and MEK/ERK) 
The RISK pathway, initially described by Yellon’s group consists of two related 
signalling cassettes: PI3K/Akt and MEK/ERK. Both act in a number of biological 
systems as anti-apoptotic pro-survival signals, classically activated by extracellular 
ligands including peptide growth factors (Yellon et al., 1999) (see Figure 2). PI3K/Akt 
and MEK/ERK have been repeatedly demonstrated as major players in mediating the 
cardioprotective effects of postconditioning in rodent models (Hausenloy, 2009). 
Tsang et al. (2004) reported that Akt was phosphorylated following six 10 sec cycles 
of reperfusion in the isolated perfused rat heart. Furthermore, endothelial NOS and 
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p70s6K were also phosphorylated more than in hearts that had undergone a standard 
reperfusion protocol. These findings were corroborated by observations that the 
classical PI3K inhibitors wortmannin and LY294002 abolished the protective effect of 
postconditioning. Subsequently, Yang et al. (2004) reported the importance of 
MEK/ERK signalling in an isolated rabbit heart model where pharmacological inhibition 
of MEK/ERK activation abolished the protection. Of note, RISK signalling is implicated 
in the cardioprotective effect of postconditioning in human atrial muscle ex vivo 
(Sivaraman et al., 2007). Many pharmacological mimetics of postconditioning have 
been shown to require the participation of either PI3K/Akt or MEK/ERK or both 
(Hausenloy, 2009). 
GSK-3β
Inhibition of glycogen synthase kinase-3β (GSK-3β) is associated with cell survival 
and may be considered as a downstream component of RISK signalling. 
Phosphorylation inhibits GSK-3β activity and thereby inhibits MPTP activity
(Juhaszova et al., 2009). However, its relative importance has been disputed in 
different models. Wagner et al. (2008) reported that both GSK-3β and ERK 
phosphorylation are significantly increased following postconditioning in rats. These 
observations were subsequently supported by further biochemical analysis 
demonstrating increased GSK3β phosphorylation following postconditioning in a rat 
global ischaemia model. In contrast, GSK-3β double knock-in mice could be protected 
with a postconditioning stimulus in a global ischaemia model (Nishino et al., 2008). 
Further evidence is required to ascertain the precise contribution of GSK-3β and how 
it may contrast in different species. 
SAFE pathway (JAK/STAT3) 
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The survivor activating factor enhancement pathway (SAFE) has been identified as an 
alternative cytoprotective pathway to RISK that is triggered by tumour necrosis factor- 
(TNF-α) and JAK/STAT signalling. Lecour’s laboratory have reported that 
pharmacological inhibition of the JAK/STAT pathway reverses the infarct limitation 
afforded by postconditioning (Lacerda et al., 2009). They also demonstrated that 
TNF-α signalling through TNFR2 and STAT3 is required to afford protection. The 
protection afforded was independent of PI3K/Akt and MEK/ERK signaling. TNFR2 
antibodies abolished protection afforded by postconditioning whereas TNFR1 
knockout mice were still conditioned (Lacerda et al., 2009). Protection observed with 
TNF-α was not present when the JAK/STAT3 inhibitor AG490 was administered at 
reperfusion (Lecour et al., 2005). The upstream activators of the SAFE pathway have 
gathered little attention to date, but it is suggested that autacoids such as those found 
upstream of the RISK cascades could be involved (Hausenloy et al., 2013). Distal to 
the SAFE pathway, it is suggested that signalling converges on the mitochondria; 
however whether the SAFE pathway converges on the same targets as RISK remains 
to be investigated thoroughly. 
cGMP/PKG pathway 
Endogenous NO derived from endothelial nitric oxide synthase (eNOS) is implicated 
in ischaemic postconditioning in several animal models. Pharmacological inhibition of 
eNOS activity abolished the protective effects of postconditioning (Tsang et al., 2004). 
Conversely, many studies have demonstrated the cytoprotective effects of 
administering an NO donor in the first few minutes of reperfusion although this effect 
of NO donors is not consistently seen (Bice et al., 2014a). NO activates soluble 
guanylyl cyclase (sGC) leading to the generation of cGMP and subsequent activation 
of cGMP-dependent protein kinase (PKG). Several lines of evidence support the 
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effectiveness of this pathway as a cardioprotective cascade (Krieg et al., 2009; Bice
et al., 2014b). In addition, cGMP/PKG signalling through particulate guanylyl cyclase 
(pGC) targeting via natriuretic peptides has also been demonstrated to afford infarct 
limitation (Burley et al., 2007). However, at present it is unclear if the PKG pathway is 
an essential component of ischaemic postconditioning and if it sits alongside the 
PI3K/Akt pathway or is distal to it (see Figure 2).  
Anti-apoptotic mechanisms 
The relative contributions that apoptosis and necrosis make in reperfusion injury have 
long been debated. Specifically the timing of apoptosis during the evolution of 
myocardial ischaemia/reperfusion injury remains unclear. Sun et al. (2009) reported 
that postconditioning limited myocardial apoptosis in rat neonatal cardiac myocytes. It 
was reported that TUNEL staining was reduced compared to controls and that ROS 
generation and intracellular calcium accumulation were reduced. Cytochrome c and 
caspase-3 have also been implicated in postconditioning signalling associated with a 
reduction in apoptosis. Penna et al. (2006) reported that these factors were reduced 
following postconditioning in an ex vivo rat model, whilst increasing the antiapoptotic 
factor Bcl-2. Inflammatory mediators including cytokines have also been associated 
with apoptotic regulation. Mechanical postconditioning has been shown to decrease 
TNFα and limited ROS formation during early reperfusion, resulting in attenuation of 
apoptosis (Kin et al., 2008). Most recently the apoptosis repressor with caspase 
recruitment domain has been shown to decrease caspase-3 activity and subsequent 
apoptosis in chick embryo myocytes following exposure to hydrogen peroxide (Wu et 
al., 2013).  
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Clinical studies of ischaemic and pharmacological postconditioning 
From the brief account above it may be inferred that a number of potential approaches 
exist for the development of postconditioning as a clinical therapeutic intervention. 
Indeed, as proof of concept, Staat et al. (2005) demonstrated that a mechanical 
postconditioning algorithm could be instituted in patients with AMI with significant 
reduction in a surrogate marker of infarct size (serum creatine kinase (CK) 
concentration). Over the last decade further clinical trials of ischaemic postconditioning 
have been conducted with mixed outcomes. In those studies that measured CK as an 
endpoint, approximately half of them reported positive outcomes (see Table 1). The 
remaining trials, all with small cohort sizes, reported neutral or negative endpoints. 
Most recently a comparatively large trial reported that 4 cycles of 60 second 
reperfusion and re-occlusion failed to reduce peak CK-MB (Hahn et al., 2013) (see 
Table 1). A number of potential explanations can be posited for the variability of clinical 
studies of ischaemic postconditioning. These include variations in postconditioning 
algorithms. These issues are discussed comprehensively in a recent review 
(Ferdinandy et al., 2014 in press) 
Pharmacological approaches to postconditioning have been assessed in a number of 
clinical studies. Here we highlight some notable completed studies, related to the 
mechanisms outlined above.  
Adenosine
Adenosine was evaluated as an adjunct to clinical reperfusion therapy prior to the 
formal identification of postconditioning (Mahaffey et al., 1999). A reduction in infarct 
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size of 33% was demonstrated in patients receiving adenosine prior to thrombolysis 
and prompted a larger trial in which the primary endpoints were development of 
congestive heart failure or six month mortality rates (Ross et al., 2005). The results of 
this 2118 patient trial were disappointing with no significant improvement in primary 
outcomes. There was however suggestion that in a subset of patients infarct size was 
reduced in patients who received the highest dose of adenosine. Furthermore, 
post-hoc analysis suggested that benefit was only observed in patients who received 
early adenosine treatment (Kloner et al., 2006). Almost half of the patients in the follow 
up trial underwent angioplasty rather than thrombolysis which also needs to be 
considered. 
cGMP/PKG pathway 
Most recently the results of the NIAMI trial have been published in which nitrite was 
administered prior to percutaneous coronary intervention (PCI) as a source of 
exogenous NO (Siddiqi et al., 2014). Extensive experimental studies have 
demonstrated the protective effects of administering nitrate, nitrite or NO donors prior 
to reperfusion. Indeed, nitrite has been shown to have vasorelaxant and anti-platelet 
properties which may be enhanced under ischaemic conditions but these are actions 
unrelated to a postconditioning effect (Rassaf et al., 2014). Post hoc analysis of 
patients who had been undergoing chronic nitrate therapy were shown to have fewer 
ST-elevated MI compared to patients who were described as nitrate-naïve (Ambrosio
et al., 2010). However, in the NIAMI trial no reduction in infarct size, measured by 
cardiac magnetic resonance (CMR) imaging was reported in patients receiving sodium 
nitrite 5 min prior to PCI. 
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Targeting the cGMP pathway and the KATP channel have also been explored in the 
clinical setting. The large multicentre J-WIND trial treated patients with atrial natriuretic 
peptide after reperfusion treatment which showed approximately 15% reduction in total 
CK release. Patients treated with the KATP channel opener nicorandil did not show any 
significant reduction in total CK release (Kitakaze et al., 2007). 
MPTP inhibition 
In a small pilot study Cys-A limited infract size by 20% compared to controls when 
measured by MRI 5 days after treatment (Piot et al., 2008). Furthermore, no adverse 
effects of Cys-A were reported. An ongoing multicentre trial (CIRCUS) is further 
investigating the potential of Cys-A as an adjunct to reperfusion, the primary endpoints 
being hospitalisation for heart failure and LV remodeling at one year. 
Other pharmacological agents 
In addition to exploring pharmacological postconditioning mimetics, other agents that 
may offer protection in the clinical reperfusion setting have been investigated. Statins, 
beta blockers, erythropoietin, glucagon-like peptide and glucose-insulin-potassium 
have all been utilised in clinical trials with varying outcomes. Two small trials in which 
erythropoietin (EPO) was administered prior to PCI reported conflicting outcomes 
(Ferrario et al., 2011; Suh et al., 2011). Similar doses were used however a 30 % 
reduction in CK-MB was reported in one and no improvement was reported in the 
other. Second and third doses were however administered at 24 and 48 h in the 
positive outcome trial. The proposed mechanism of action for EPO protection is said 
to involve inhibition of the myocardial inflammatory response which may have a 
delayed component explaining the differences in clinical outcomes.  
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The challenges and opportunities for successful translation 
The picture obtained so far is that myocardial ischaemic postconditioning (e.g. during 
PCI for AMI) has the potential to limit infarct size but is of variable efficacy. Studies 
with pharmacological mimetic approaches (e.g. adjuncts to PCI or thrombolysis for 
AMI) that target the postconditioning signalling pathways described in experimental 
studies have not been overwhelmingly positive. There are likely to be multiple 
reasons for these inconsistent findings. They include study design features e.g. 
(patient inclusion criteria, timing of drug administration); technical limitations to 
accurate endpoint assessment (e.g. normalised infarct size measurement in 
humans); attenuation or overwhelming of the postconditioning signalling 
mechanisms in patients. The latter potentially represents the greatest challenge for 
successful translation of postconditioning into the therapeutic arena.  
The confounding effect of comorbidities 
The majority of experimental studies of ischaemic postconditioning or pharmacological 
postconditioning mimetics have been performed in healthy, juvenile male animals. 
These models are devoid of associated risk factors for cardiovascular disease and do 
not represent the comorbidities often present in the clinical setting. It is now clear that 
many of the risk factors and comorbid conditions that contribute to or are present in 
coronary artery disease (senescence, gender-related hormonal background, 
dyslipidaemia, hypertension, diabetes etc.) modify the signalling pathways 
underpinning postconditioning (Downey et al., 2009; Przyklenk, 2013; Vander Heide
et al., 2013). In experimental models which address these factors, both ischaemic and 
pharmacological postconditioning effects may be abolished or severely attenuated 
because of biochemical perturbations brought about by these conditions. The worrying 
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possibility that the majority of experimental models have not predicted or recapitulated 
clinical reality might be regarded by some as the killer blow for successful development 
of clinical postconditioning and may go some way to explaining the massive variability 
in clinical trials to date. However, we are not so pessimistic. It seems plausible that at 
least with some of these comorbidities, postconditioning is not abolished absolutely, 
but rather the threshold for activation of the pathways is raised. For example, in 
experimental studies where protection by either ischaemic postconditioning or Cys-A 
was abolished in diabetic hearts, combination of both interventions restored protection 
suggesting that the diabetic heart could be protected if an increased cardioprotective 
threshold could be met (Badalzadeh et al., 2012). Moreover, in some cases, treatment 
or resolution of the comorbidity restores postconditioning’s effect. For example, in a 
rabbit model postconditioning alone could not limit infarct size in high cholesterol fed 
animals. However, administration of pravastatin was able to afford protection in these 
resistant animals, an effect that was blocked by eNOS inhibition (Andreadou et al., 
2012).
The confounding effect of current drug therapies 
Another intriguing possible explanation for variability in clinical postconditioning 
studies is that many patients are in fact already in a maximally conditioned state as a 
result of their existing drug therapy. Bell and Yellon (2014) have recently proposed a 
“success hypothesis” suggesting that many, perhaps the majority of, patients 
presenting with acute coronary syndromes (ACS) are already conditioned by the 
polypharmaceutical regimen of drugs that they are already taking. Statins, ACE 
inhibitors, beta blockers and opioid analgesics are all commonly prescribed to these 
patients and indeed have all been shown to be cardioprotective or to have 
conditioning-like properties in the experimental setting. On the other hand, accounts 
21 
of the effect of these drugs to inhibit conditioning mechanisms have been made in 
some studies. The term “hidden cardiotoxicity” has been proposed which suggests 
that some of the adjunct therapies used may increase the threshold for 
cardioprotection (Ferdinandy et al., 2014). 
Clinical trial design and translating postconditioning 
The disparity between the experimental studies and the clinical trial data so far 
obtained suggests that translation – both from bench to bedside and vice versa –
needs to be improved. As identified above, experimental study design needs to be 
refined for further mechanistic studies to represent better the clinical setting. At the 
very least experimental models in which comorbidities can be simulated should be 
used following initial mechanistic studies. It is clear that we need to focus on building 
on the well-documented signalling cascades and the spatial and temporal 
modifications to signalling in diseased states. 
To date, the majority of clinical trials assessing pharmacological postconditioning 
mimetics have been unsuccessful or of only modest benefit (see Table 1). But their 
limited success may be explained in two ways. First, the design of the pre-clinical 
animal experiments may fail to recapitulate the complexities of the clinical situation 
and this leads to inappropriate target selection. Second, the design of clinical trials 
needs to account for the massive heterogeneity of the patient population and the 
currently limited ability to quantify tissue salvage or measure infarct size standardised 
to risk zone size accurately and reliably. Unlike laboratory species, the clinical 
population presenting with AMI is a heterogenous mix of high-risk and low-risk 
patients, those with large infarcts and those with small infarcts. Unlike the laboratory 
experiment, the ischaemic risk zone size, the duration of the ischaemic episode and 
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the speed of successful reperfusion are highly variable. Perhaps most importantly, the 
high degree of standardisation of infarct size measurement required in the 
experimental laboratory is effectively unachievable in the clinical setting with presently 
available methods. 
Thus, it seems unlikely that we will achieve a postconditioning intervention that 
guarantees benefit for all. Much more likely is that an agent which is safe and easy to 
administer as a single dose – probably a repurposed drug such as Cys-A - could be 
given to all AMI patients undergoing reperfusion with the expectation that a proportion 
might benefit. Given the very large number of patients undergoing reperfusion therapy, 
the global benefit of such an approach could be large. 
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Table 1. Clinical trials utilising mechanical and pharmacological postconditioning in patients presenting with STEMI 
Study/Reference Treatment protocol n number 
Tx/Control
Effect
IPOC
Laskey 2005 2 cycles of 90 s R/I 10/7 Improved ST-segment resolution, no difference in peak CK.
Staat et al. 2005 4 cycles of 60s R/I 16/14 Improves ST-segment resolution, reduction in 72 h CK.
Ma et al. 2006 3 cycles of 30 s R/I 49/45 Improved WMSI, endothelial function, reduced CK (NS).
Yang et al. 2007 3 cycles of 60 s R/I 23/18 27% reduction in 72 h CK.
Laskey et al. 2008 2 cycles of 90 s R/I 13/11 Improved ST-segment resolution. Improved coronary flow 
velocity.
Thiabault et al. 2008 4 cycles of 60 s R/I 17/21 40% reduction in CK. 47% reduction in troponin 1.
Zhao et al. 2008 3 cycles of 30 or 60 s R/I 49/26 Reduced apoptosis at 7 days.
Lønborg et al. 2010 4 cycles of 60 s R/I 59/59 19% relative reduction of MI at 3 months. 31% increase in 
myocardial salvage.
Sörensson et al. 2010 4 cycles of 60 s R/I 38/38 Neutral outcomes.
Xue 2010 4 cycles of 60 s R/I 23/20 Reduction in infarct size (SPECT).
Garcia et al. 2011 4 cycles of 30 s R/I 22/21 Reduction in CK and improved LVEF.
Freixa 2012 4 cycles of 60 s R/I 39/40 No improvement in infarct size (CMR) or LVEF.
Tarantini et al. 2012 4 cycles of 60 s R/I 39/39 No reduction in infarct size at 30 days (CMR).
Thury 2012 4 cycles of 60 s R/I 25/25 Reduction in infarct size (CMR) and CK.
Dwyer 2013 4 cycles of 30 s R/I 51/51 NS reduction in infarct size (CMR).
Hahn et al. 2013 4 cycles of 60 s R/I 350/350 No improvement in ST-segment resolution.
PI3K/Akt
Nikolaidis et al. 2004 GLP-1 infusion for 72 h post-PCI 10/11 Improved LVEF.
Lønborg et al. 2012 Exenatide 0.12 μg/min 15 min pre-PCI for 6 h 54/51 Reduced infarct size at 90 days (CMR).
Erythropoietin
Ferrario et al. 2011 33000 IU bolus EPO pre-PCI, then 24, 48 h later 15/15 30% reduction in CK-MB.
Suh et al. 2011 50 IU/kg EPO bolus pre-PCI 29/28 No improvement in CK, CK-MB or CMR at 96 h.
CREATE-ECLA 2005 GIK infusion for 24 h 10091/10110 Neutral outcome.
Kim et al. 2010 80 vs. 10 mg oral atorva-statin pre-PCI 86/85 No difference in CK-MB or troponin.
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GPCR
Ross et al. 2005 70 μg/kg/min adenosine for 3 h within 15 min 
R
713/703 Reduction in infarct size (SPECT) in sub study (n=243).
Kloner et al. 2006 50 or 70 μg/kg/min adenosine within 15 min R 716/350 Reduction in 1 and 6 month mortality.
cGMP/PKG
Kitakaze et al. 2007 72 h carperitide infusion post-PCI 277/292 15% reduced total CK. Improved reperfusion.
Siddiqi et al. 2014 70 μmol IV sodium nitrite over 5 min pre-PCI 118/111 No reduction in infarct size (CMR).
Mitochondria
Kitakaze et al. 2007 Nicorandil IV bolus then 24 h infusion 276/269 No difference in total CK or LVEF.
Piot et al. 2008 Cyclosporine-A 2.5 mg/kg IV 10 min pre-PCI 30/28 Reduction in total CK. 27 patients 20% reduction in MI size (CMR).
Mewton et al. 210 Cyclosporine-A 2.5 mg/kg IV 10 min pre-PCI 28/0 24% reduction in MI size (CMR).
R/I: cycle of reperfusion and ischaemia, CK: creatine kinase, CK-MB: creatine kinase assay, MI: myocardial infarction, LVEF: left ventricular ejection fraction, 
CMR: cardiac magnetic resonance, MRI: magnetic resonance imaging, WMSI: wall motion score index, SPECT: single-photon emission computer 
tomography, NS: not significant. 
Table 1. Clinical trials utilising mechanical and pharmacological postconditioning in patients presenting with STEMI R/I: cycle of reperfusion and ischaemia, 
CK: creatine kinase, CK-MB: creatine kinase assay, MI: myocardial infarction, LVEF: left ventricular ejection fraction, CMR: cardiac magnetic resonance, MRI: 
magnetic resonance imaging, WMSI: wall motion score index, SPECT: single-photon emission computer tomography, NS: not significant. 
(Nikolaidis et al., 2004; Laskey, 2005; Ross et al., 2005; Staat et al., 2005; The, 2005; Kloner et al., 2006; Ma et al., 2006; Kitakaze et al., 2007; Yang et al., 
2007; Laskey et al., 2008; Piot et al., 2008; Thibault et al., 2008; Zhao et al., 2009; Kim et al., 2010; Mewton et al., 2010; Sörensson et al., 2010; Xue et al., 
2010; Ferrario et al., 2011; Garcia et al., 2011; Suh et al., 2011; Freixa et al., 2012; Lønborg et al., 2012; Tarantini et al., 2012; Thuny et al., 2012; Dwyer et 
al., 2013; Hahn et al., 2013; Siddiqi et al., 2014) 
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Figures legends 
Figure 1. Schematic representation of myocardial postconditioning protocols and 
reported infarct limitation afforded by these interventions. Index ischaemia, typically of 
30 min duration is followed by intermittent reperfusion-reocclusion of the coronary 
artery-Ischaemic postconditioning. Similarly when the reocclusion cycles are delayed 
by as little as 60 s, infarct limitation is no longer afforded. Pharmacological 
postconditioning typically involves the administration of a postconditioning mimetic 
during early reperfusion. Remote postconditioning is afforded by occlusion-reperfusion 
cycles of an artery distal to the myocardium, typically a limb. Modified reperfusion is 
initiated by gradual reperfusing the occluded area of the myocardium over several 
seconds. Temporarily reducing the pH during the first minutes of reperfusion can also 
afford infarct limitation. I/R- infarct to risk zone size, IPOC- ischaemic postconditioning, 
GrR- gradual reperfusion, AcR- acidified reperfusion, RPOC- remote postconditioning, 
BNP- brain natriuretic peptide, BAY- cGMP elevating compounds. 
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Figure 2. Schematic representation of the identified components of postconditioning 
signalling in the myocardium. Autacoid factors such as adenosine and opioids along 
with other extracellular factors initiate cytoprotective signalling through their 
sarcolemmal receptors. Three distinct signalling pathways have been reported, 
including RISK, which involves PI3K/Akt and ERK and distal inhibition of GSK-3β. 
cGMP/PKG signalling through natriuretic peptides and sGC activation is identified as 
an additional pathway distally targeting mitochondrial potassium channels. SAFE 
whose major components are TNFα and JAK/STAT has also been demonstrated to 
play a role in postconditioning. Although described as distinct pathways, their 
cytoprotective actions are demonstrated to culminate on the mitochondria, specifically 
inhibition of the MPTP. It remains to be fully investigated as to what extent these 
pathways interact and colocalize. TNF-R – TNF receptor, RTK – receptor tyrosine 
kinase, GPCR – G-protein coupled receptor, NPR – natriuretic peptide receptor, JAK 
– Janus kinase, STAT3 - Signal Transducer and Activator of Transcription, 
PI3K - Phosphatidylinositol-4,5-bisphosphate 3-kinase, Akt – protein kinase B, ERK –
extracellular regulated kinase, eNOS – endothelial nitric oxide synthase, sGC –
soluble guanylyl cyclase, cGMP – 3’,5’-cyclic guanosine monophosphate, PKG –
cGMP dependent protein kinase, SERCA – sarcoplasmic/endoplasmic reticulum 
calcium ATPase, SR – sarcoplasmic reticulum, MKATP – mitochondrial KATP channel, 
GSK-3β – glycogen synthase kinase-3β, CYP-D – cyclophilin D, MPTP –
mitochondrial permeability transition pore.
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